Physician profile
John M Limperis
NPI 1831204353
$1,033.33
in general payments reported to CMS, 2019-2025
12 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2022: $33.47 · 2023: $263 · 2024: $294 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $266.87 | 2023-2024 | Ffrct |
| Dexcom, INC. | $175.70 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Medtronic USA, INC. | $141.80 | 2019 | |
| Stryker Corporation | $104.62 | 2024 | Infinity |
| Davol INC. | $90.91 | 2025 | Phasix Mesh |
| Glaxosmithkline, LLC. | $64.15 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $49.59 | 2023-2024 | Mounjaro |
| Amgen INC. | $44.71 | 2025 | Repatha, Otezla |
| Astellas Pharma US INC | $33.47 | 2022 | |
| Pfizer INC. | $24.21 | 2023 | |
| Novo Nordisk INC | $21.20 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Limperis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.